公开(公告)号：WO2015164160A1

公开(公告)日：2015-10-29

申请号：PCT/US2015/026060

申请日：2015-04-16

Applicant: MERCK SHARP & DOHME CORP. ,  MCNEVIN, Michael ,  LOHANI, Sachin

Inventor： MCNEVIN, Michael ,  LOHANI, Sachin

IPC: A61K31/551 ,  A61K31/423 ,  C07D413/14

CPC classification number: C07D413/14 ,  A61K31/551 ,  C07B2200/13 ,  C07C305/04 ,  C07C305/06 ,  C07C309/04 ,  C07C309/30 ,  C07C309/66

Abstract: The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.

Abstract translation: 本发明涉及suvorexant的药学上可接受的盐，其是食欲素受体的拮抗剂。 suvorexant的药学上可接受的盐可用于治疗或预防涉及食欲素受体的神经和精神疾病和疾病。 本发明进一步涉及包含药学上可接受的盐酸盐的药物组合物。

公开(公告)号：WO2009151997A1

公开(公告)日：2009-12-17

申请号：PCT/US2009/045917

申请日：2009-06-02

Applicant: MERCK & CO., INC. ,  BANYU PHARMACEUTICAL CO., LTD. ,  FURUKAWA, Shuntaro ,  IKENO, Taketo ,  KATO, Shinji ,  KAWASAKI, Masashi ,  KOJIMA, Hisaki ,  MINAGAWA, Wataru ,  SAWADA, Naotaka ,  YAMAMOTO, Fuyuki ,  LOHANI, Sachin ,  WANG, Yaling

Inventor： FURUKAWA, Shuntaro ,  IKENO, Taketo ,  KATO, Shinji ,  KAWASAKI, Masashi ,  KOJIMA, Hisaki ,  MINAGAWA, Wataru ,  SAWADA, Naotaka ,  YAMAMOTO, Fuyuki ,  LOHANI, Sachin ,  WANG, Yaling

IPC: C07D487/00 ,  A61K31/505

CPC classification number: C07D487/04

Abstract: The present invention relates to a process for producing a hydrate of 3-(2,6-dichlorophenyl)-4-imino-7-[(2'-methyl-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-7'-yl)amino]-3,4-dihydropyrimido[4,5-d] pyrimidin-2(1H)-one (Compound A) or of a pharmaceutically acceptable salt of Compound A and a crystalline form of Compound A or of a pharmaceutically acceptable salt of Compound A, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.

Abstract translation: 本发明涉及一种3-（2,6-二氯苯基）-4-亚氨基-7 - [（2'-甲基-2'，3'-二氢-1'H-螺[环丙烷 -1,4'-异喹啉] -7'-基）氨基] -3,4-二氢嘧啶并[4,5-d]嘧啶-2（1H） - 酮（化合物A）或化合物A的药学上可接受的盐 以及化合物A或化合物A的药学上可接受的盐的结晶形式，其可用于治疗各种癌症作为激酶抑制剂，特别是作为威尔激酶抑制剂的领域。